Drug
Amlitelimab clinical trials
Also written SAR445229 and KY1005.
- studies test it
- 20
- open now
- 1
- in phase 3
- 6
- first study started
- 2017
Keep track of what changes. Save the amlitelimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
20 studies that test it; most in 2024 (7)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 6 |
| 2024 | 7 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 11
- Phase 3
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 19 · Other 1
Sanofi (15) · Kymab Limited (4) · Scleroderma Research Foundation, Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses amlitelimab is read from its arms, and is right about nine times in ten.
Testing it · 20
- Platform Clinical Study for Conquering SclerodermaRecruitingPhase 2Scleroderma Research Foundation, Inc.NCT06195072Written as Amlitelimab
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK InhibitorActive, not recruitingPhase 3SanofiNCT06241118Written as Amlitelimab
- Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical TrialsActive, not recruitingPhase 2/3SanofiNCT05492578Written as Amlitelimab
- Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical StudyTerminatedPhase 2SanofiNCT06033833Written as Amlitelimab
- A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac DiseaseActive, not recruitingPhase 2SanofiNCT06557772Written as Amlitelimab
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical CorticosteroidsCompletedPhase 3SanofiNCT06224348Written as Amlitelimab
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)CompletedPhase 3SanofiNCT06181435Written as Amlitelimab
- A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With PlaceboCompletedPhase 2SanofiNCT06015308Written as Amlitelimab
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia AreataTerminatedPhase 2SanofiNCT06444451Written as Amlitelimab
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisCompletedPhase 3SanofiNCT06130566Written as Amlitelimab
- A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic DermatitisActive, not recruitingPhase 3SanofiNCT06407934Written as Amlitelimab
- Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic DermatitisActive, not recruitingPhase 2SanofiNCT05769777Written as Amlitelimab
- An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 SubstratesCompletedPhase 1SanofiNCT06686628Written as Amlitelimab
- A Bioequivalence Study of Amlitelimab Delivered by 2 Different Devices in Healthy Adult ParticipantsCompletedPhase 1SanofiNCT07146750Written as SAR445229
- Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe AsthmaCompletedPhase 2SanofiNCT05421598Written as Amlitelimab
- Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis SuppurativaTerminatedPhase 2SanofiNCT06118099Written as Amlitelimab
- Study Testing Response Effect of KY1005 Against Moderate-to-Severe Atopic Dermatitis, The STREAM-AD StudyCompletedPhase 2Kymab LimitedNCT05131477Written as Amlitelimab
- A Study of KY1005 in Patients With Moderate to Severe Atopic DermatitisCompletedPhase 2Kymab LimitedNCT03754309Written as KY1005
- A Study of Subcutaneous KY1005 in Healthy VolunteersCompletedPhase 1Kymab LimitedNCT04449939Written as KY1005
- A Study of KY1005 in Healthy VolunteersCompletedPhase 1Kymab LimitedNCT03161288Written as KY1005
Codes
What other systems call amlitelimab · ClinicalTrials.gg INT018632
- UNII (FDA) YZ6BH6TN8PAMLITELIMABOne source FDA
- NCI Thesaurus C179073AmlitelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | YZ6BH6TN8P | AMLITELIMAB | One source FDA |
| NCI Thesaurus | C179073 | Amlitelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.